Kuaishou-W (01024) announced on December 19th that it will spend 49.95 million Hong Kong dollars to repurchase 755,000 shares.
Kuaishou-W (01024) announced on December 19, 2025, that the company will spend 49.9509 million Hong Kong dollars to repurchase 755,000 shares, with a repurchase price of 65.4-66.6 Hong Kong dollars per share. On the same day, 27,700 shares were issued based on the exercise of options under the first public offering share purchase plan; 3,100 shares were issued based on the exercise of options under the pre-IPO employee share ownership plan; 2.609 million repurchased shares were cancelled; and 6.3541 million Class A ordinary shares were converted to Class B ordinary shares.
KUAISHOU-W (01024) announced that on December 19, 2025, the company repurchased 755,000 shares at a cost of 49.95 million Hong Kong dollars, with a repurchase price of 65.4-66.6 Hong Kong dollars per share. On the same day, the company also issued 27,700 shares under the exercise of stock purchase rights from the initial public offering, and 3,100 shares under the exercise of employee share ownership plan rights before the initial public offering. Additionally, 2.609 million repurchased shares were cancelled, and 6.3541 million Class A ordinary shares were converted to Class B ordinary shares.
Related Articles
CHINA LESSO (02128) and Guangdong Liansu Electric have signed a parts supply agreement.
Jiangsu Hengrui Pharmaceuticals (01276): SHR-2906 Injection Obtains Drug Clinical Trial Approval Letter.
Jiangsu Hengrui Pharmaceuticals (01276): SHR-9539 injection, HRS-3738 tablets received the approval notice for drug clinical trials.
CHINA LESSO (02128) and Guangdong Liansu Electric have signed a parts supply agreement.
Jiangsu Hengrui Pharmaceuticals (01276): SHR-2906 Injection Obtains Drug Clinical Trial Approval Letter.
Jiangsu Hengrui Pharmaceuticals (01276): SHR-9539 injection, HRS-3738 tablets received the approval notice for drug clinical trials.
